Literature DB >> 9079206

Analytical development for low molecular weight xenobiotic compounds.

H H Maurer1, J W Arlt, T Kraemer, C J Schmitt, A A Weber.   

Abstract

Specific and sensitive detection or precise quantification of xenobiotics in biosamples (e.g. blood, urine, saliva, sweat, hair) are great challenges in analytical toxicology. GC-MS is the most sensitive, specific and universal analytical method for low mass xenobiotics. Precise quantification can be performed using the selected ion mode (SIM) and stable isotopes as internal standards. Negative chemical ionization (NCI) can improve severalfold the sensitivity for the determination of compounds with electronegative sites (e.g. halogens). For screening and identification of most of the basic and neutral drugs (e.g. drugs of abuse, psychotropics, hypnotics, analgesics, cardiacs) in urine, a systematic toxicological analysis procedure (STA) was developed using GC-MS after acid hydrolysis, extraction and acetylation. for detection of acidic xenobiotics (e.g. anticoagulants, ACE inhibitors, diuretics, antirheumatics) in urine, a further GC-MS procedure was developed using extractive alkylation. For the detection of non-volatile xenobiotics (e.g. toxic peptides like alpha- and beta-amanitin or phase II metabolites) electrospray LC-MS procedures were developed. The procedures and examples show that in analytical toxicology GC-MS is the method of choice for low mass xenobiotics while LC-MS is that for non-volatiles.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9079206     DOI: 10.1007/978-3-642-60682-3_17

Source DB:  PubMed          Journal:  Arch Toxicol Suppl        ISSN: 0171-9750


  1 in total

1.  Evaluation of an improved general unknown screening procedure using liquid chromatography-electrospray-mass spectrometry by comparison with gas chromatography and high-performance liquid-chromatography--diode array detection.

Authors:  Franck Saint-Marcoux; Gérard Lachâtre; Pierre Marquet
Journal:  J Am Soc Mass Spectrom       Date:  2003-01       Impact factor: 3.109

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.